SynthesisArteriosclerosis, thrombosis, and vascular biology2020
Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses.
Synthesis in Arteriosclerosis, thrombosis, and vascular biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06163924 (To Investigate the Effect of Multidisciplinary Care Approach on Cardiovascular Risk Modification in Prostate Cancer Patients Receiving Androgen Deprivation Therapy), which is not on this map. Cited by 82 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
To Investigate the Effect of Multidisciplinary Care Approach on Cardiovascular Risk Modification in Prostate Cancer Patients Receiving Androgen Deprivation Therapy
Who cites it
82 citing papers in PubMed, 4 syntheses or guidelines pooled it, 153 citations in OpenAlex.
- Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis.Prostate cancer and prostatic diseases · 2025Pooled it
- Androgen deprivation therapy use and the risk of heart failure in patients with prostate cancer: a systematic review and meta-analysis.BMC cardiovascular disorders · 2024Pooled it
- Cardiovascular mortality in people with cancer compared to the general population: A systematic review and meta-analysis.Cancer medicine · 2024Pooled it
- Pooled it
- Mediterranean Style Dietary Pattern with High Intensity Interval Training in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Pilot Randomised Control Trial.International journal of environmental research and public health · 2022Trial
- Cardiovascular Complications Associated with Uro-Oncology Treatments-A Primer for the Clinician.Diagnostics (Basel, Switzerland) · 2026Review
- Cardiac function in zebrafish embryos is linked to an androgen receptor-adrenomedullin-proepicardium axis.Cell communication and signaling : CCS · 2026Article
- [Reassessing androgen deprivation therapy (ADT) in older men with advanced prostate cancer: when to use, when to discontinue, and role as monotherapy?]Urologie (Heidelberg, Germany) · 2026Review
- Impact of androgen deprivation therapy on the cardiovascular functions in men with prostate cancer.International urology and nephrology · 2026Observational
- Enzalutamide in biochemically recurrent prostate cancer: clinical implications from EMBARK for real-world practice.Future oncology (London, England) · 2026Article
- Genetic evidence against a causal relationship between myocardial infarction and urological malignancies.The Canadian journal of urology · 2026Article
- Associations of fine particulate matter pollution components with overall, prostate cancer, and cardiovascular disease mortality in men with prostate cancer: A cohort study.Environmental research · 2026Article
- Diabetes and cancer: therapeutic implications.Cardio-oncology (London, England) · 2026Review
- Association between polygenic risk scores and cardiovascular events in prostate cancer patients receiving androgen deprivation therapy in Han Chinese.Cardio-oncology (London, England) · 2026Article
- Long-term assessment of adverse cardiovascular events in men receiving intermittent androgen deprivation therapy following radical prostatectomy.BJUI compass · 2025Article
- Clonal Hematopoiesis and Solid Cancers.Cancer science · 2025Review
- Rapid Modulation of Circulating Adipokines and Inflammatory Cytokines in Localized Prostate Cancer Following Short-Term Leuprolide Therapy.Clinical genitourinary cancer · 2025Article
- Cognitive Impairment in Prostate Cancer Patients Receiving Androgen Deprivation Therapy: A Scoping Review.Cancers · 2025Review
- Article
- Androgen Deprivation Therapy-Induced Muscle Loss and Fat Gain Predict Cardiovascular Events in Prostate Cancer Patients.Journal of cachexia, sarcopenia and muscle · 2025Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Androgen deprivation therapy is a cornerstone of prostate cancer treatment. Pharmacological androgen deprivation includes gonadotropin-releasing hormone agonism and antagonism, androgen receptor inhibition, and CYP17 (cytochrome P450 17A1) inhibition. Studies in the past decade have raised concerns about the potential for androgen deprivation therapy to increase the risk of adverse cardiovascular events such as myocardial infarction, stroke, and cardiovascular mortality, possibly by exacerbating cardiovascular risk factors. In this review, we summarize existing data on the cardiovascular effects of androgen deprivation therapy. Among the therapies, abiraterone stands out for increasing risk of cardiac events in meta-analyses of both randomized controlled trials and observational studies. We find a divergence between observational studies, which show consistent positive associations between androgen deprivation therapy use and cardiovascular disease, and randomized controlled trials, which do not show these associations reproducibly.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.